Gland Pharma Limited announced key board decisions following its meeting on June 15, 2026. The Board approved the re-appointment of Mr. Udo Jahannes Vetter as Independent Director for a second five-year term, effective July 21, 2026. Additionally, Mr. William Robert Keller was appointed as an Additional Director (Non-Executive – Independent Director) from June 15, 2026. The company also accepted the resignation of Mr. Satyanarayana Murthy Chavali as Independent Director due to a potential conflict of interest.
Gland Pharma Board Meeting Outcomes
On June 15, 2026, the Board of Directors of Gland Pharma Limited convened a meeting where several significant decisions were made concerning its directorship. These decisions align with the company’s commitment to corporate governance and strategic growth.
Director Re-appointments and New Appointments
Re-appointment of Mr. Udo Jahannes Vetter
The Board has approved the re-appointment of Mr. Udo Jahannes Vetter (DIN: 00707474) as an Independent Director of the Company. This appointment will be for a second term of five consecutive years, commencing from July 21, 2026, and concluding on July 20, 2031. The necessary member approval for this re-appointment will be obtained through postal ballot and e-voting within the stipulated timelines.
Appointment of Mr. William Robert Keller
Mr. William Robert Keller (DIN: 11593622) has been appointed as an Additional Director (Non-Executive – Independent Director) of the Company, effective June 15, 2026. Mr. Keller brings extensive international experience, currently serving as an Independent Director at Wuxi Biologics and Hua Medicine, both listed on the Hongkong Stock Exchange. His appointment will also require member approval via postal ballot and e-voting.
Resignation of Mr. Satyanarayana Murthy Chavali
Reason for Resignation
The Board has accepted the resignation of Mr. Satyanarayana Murthy Chavali as an Independent Director, effective from the close of business hours on June 15, 2026. Mr. Chavali’s decision stems from a potential conflict of interest arising from a business segment that a company he promotes and directs may enter, which could overlap with Gland Pharma’s proposed business activities.
Mr. Chavali confirmed that this potential conflict of interest is the sole reason for his resignation, emphasizing his commitment to maintaining the highest standards of corporate governance.
Appreciation for Service
The Board of Directors and the entire Gland Pharma family expressed their deep appreciation for the long-standing leadership and contribution of Mr. C.S.N. Murthy (referring to Mr. Satyanarayana Murthy Chavali in the continuation sheet), who has been associated with the Company since November 20, 2018. His contributions have been instrumental in the company’s success.
Consequent Board and Committee Realignments
Following these changes, the Board of Directors of Gland Pharma International Pte. Ltd. (a material subsidiary) has been reconstituted. Mr. Essaji Goolam Vahanvati, an Independent Director, has been appointed to the Board of this subsidiary, effective June 15, 2026.
Furthermore, the Committees of the Board have been realigned to reflect the changes in directorship. Key adjustments include:
- Audit Committee: Mr. William Robert Keller appointed as a member, and Mr. Essaji Goolam Vahanvati appointed as Chairman.
- Nomination & Remuneration Committee: Mr. William Robert Keller appointed as a member, and Mr. Udo J Vetter appointed as Chairman.
- Stakeholders’ Relationship & Share Transfer Committee: Mr. Udo J Vetter appointed as Chairman.
- ESOP Compensation Committee: Mr. Srinivas Sadu appointed as a member, and Mr. Udo J Vetter appointed as Chairman.
The Board meeting commenced at 15:00 Hrs. IST and concluded at 15:50 Hrs. IST.
Source: BSE
